Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Cullinan Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336717
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | $44,437 | $61,030 | $86,560 | $102,489 |
| General and administrative | 12,817 | 14,768 | 24,391 | 28,305 |
| Total operating expenses | 57,254 | 75,798 | 110,951 | 130,794 |
| Loss from operations | (57,254) | (75,798) | (110,951) | (130,794) |
| Other income (expense): | ||||
| Interest income | 3,648 | 5,924 | 7,746 | 12,504 |
| Other expense, net | (98) | (181) | (160) | (266) |
Item 1. Financial Statements.
FAQ
- What is Cullinan Therapeutics, Inc.'s R&D?
- Cullinan Therapeutics, Inc. (CGEM) reported R&D of $44.44M in Q2 2026.
- How has Cullinan Therapeutics, Inc.'s R&D changed year-over-year?
- Cullinan Therapeutics, Inc.'s R&D decreased by 27.2% year-over-year, from $61.03M to $44.44M.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Cullinan Therapeutics, Inc.'s R&D has grown at a 34.2% compound annual growth rate (CAGR), from $57.75M to $187.4M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Cullinan Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude